泛KRAS抑制剂BI-2493和BI-2865在具有KRAS野生类型等位基扩增的瘤中显示出强大的抗瘤活性
Antonio Tedeschi1, Fiorella Schischlik1, Francesca Rocchetti1
1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Molecular cancer therapeutics
|December 23, 2024
概括
新的泛KRAS抑制剂,BI-2493和BI-2865,在临床前模型中显示出强大的抗瘤活性. KRAS野生型 (WT) 放大瘤对这些"关闭"状态抑制剂特别敏感,提供了一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 克拉斯突变驱动各种癌症,选择性抑制剂如索托拉西布向特定的等位基因.
- 克拉斯野生型 (WT) 放大是一种明显的致癌驱动因素,特别是在胃食道癌症中.
- 针对KRAS WT放大提供了一个潜在的治疗途径,超出了KRAS突变特异性抑制剂.
研究的目的:
- 在临床前癌症模型中评估新型泛KRAS抑制剂BI-2493和BI-2865的疗效.
- 为了确定赋予这些泛-KRAS抑制剂敏感性的特定遗传变化.
- 探索向KRAS WT放大的治疗潜力.
主要方法:
- 在混合物中同时利用分析相对抑制 (PRISM) 试验对超过900个癌细胞系的BI-2493进行高通量查.
- 在体外和体内评估泛KRAS抑制剂的抗增殖活性.
- 与KRAS基因拷贝数和突变状态相关联的药物敏感性.
主要成果:
- 全KRAS抑制剂BI-2493和BI-2865在临床前模型中显示出强大的抗瘤活性.
- 具有KRAS野生型 (WT) 放大 (副本数>7) 的癌细胞系对这些抑制剂表现出最高的敏感性.
- 这些抑制剂向KRAS的非活性"关闭"状态,在KRAS WT增强模型中显示出优越的疗效,而不是"开启"状态的抑制剂.
结论:
- 直接的药理抑制KRAS对KRAS WT放大癌症有效.
- KRAS WT放大是对"关闭"状态泛KRAS抑制剂敏感性的预测生物标志物.
- BI-2493和BI-2865代表了一种针对癌症的新疗法策略,该策略包含KRAS WT放大.
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


